<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03492736</url>
  </required_header>
  <id_info>
    <org_study_id>180013</org_study_id>
    <nct_id>NCT03492736</nct_id>
  </id_info>
  <brief_title>Effects of Melatonin in Untreated Obstructive Sleep Apnea</brief_title>
  <official_title>Does Melatonin Improve Neurocognitive Function, Cardiovascular Outcomes and Control of Breathing in Untreated Obstructive Sleep Apnea?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naomi Deacon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have previously shown that 1 week of 10mg Melatonin improves sleep
      consolidation in untreated obstructive sleep apnea (OSA) patients. This study aims to extend
      on those findings to determine if longer treatment of Melatonin improves other outcomes in
      untreated OSA patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intermittent hypoxia (low oxygen), sleep fragmentation and restriction are characteristic of
      obstructive sleep apnea (OSA) and cause mental deficits and cardiovascular disease (CVD).
      Melatonin (MLT) is a hormone with sleep promoting properties and the investigators have found
      7 days 10mg MLT treatment significantly increases sleep consolidation in untreated OSA. Thus,
      melatonin could improve mental function. MLT also has potent antioxidant, anti-inflammatory
      and anti-hypertensive properties. In humans with CVD and metabolic disorder exogenous MLT
      improves a wide range of cardio-metabolic outcomes. In rat models of OSA, MLT completely
      blocks intermittent hypoxia induced cardiovascular damage and brain cell death. Intermittent
      hypoxia also induces lasting changes in the neural control of breathing, which worsens OSA.
      Experimentally antioxidants block the induction of changes to neural control of breathing.
      Thus MLT may also normalize the control of breathing and reduce the severity of OSA. Given
      these findings, the hypothesis is that MLT will improve mental function, cardiovascular
      outcomes and control of breathing in untreated OSA.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, placebo-controlled, parallel</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PHQ-9 score</measure>
    <time_frame>baseline versus on the 30th day of treatment</time_frame>
    <description>9 Questions relating to depressive symptoms. Answers to each question rank from 0-3. Minimum total score = 0, maximum total score = 27, with &gt;=10 indicating clinically significant moderate severity depressive symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reactive Hyperemia Index</measure>
    <time_frame>baseline versus on the 30th day of treatment</time_frame>
    <description>Endothelial function is calculated as the ratio between the magnitude of the mean post-occlusion pulse wave amplitude and mean baseline pulse wave amplitude.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Hypoxic ventilatory response</measure>
    <time_frame>baseline versus on the 30th day of treatment</time_frame>
    <description>change in ventilation per change in expiratory CO2 during sustained hypoxia</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 days 10mg Melatonin taken nightly 1 hour before bed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>30 days placebo taken nightly 1 hour before bed</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>30 days 10mg Melatonin taken nightly 1 hour before bed</description>
    <arm_group_label>Melatonin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>30 days placebo taken nightly 1 hour before bed</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate-severe OSA (AHI ≥15/hr)

        Exclusion Criteria:

          -  non-English speakers (due to necessity to complete neurocognitive testing)

          -  other sleep disorders

          -  history of driving or other accidents due to sleepiness or an Epworth score (ESS)&gt; 18

          -  pregnant

          -  smokers (quit ≥ 1 year ago acceptable)

          -  diabetes

          -  cardiac (other than hypertension), pulmonary, renal, neurologic, neuromuscular or
             hepatic disease

          -  Substantial alcohol (&gt;3oz/day) or use of illicit drugs

          -  psychiatric disorders (other than depression or anxiety)

          -  current MLT use or use within last 6 months

          -  beta blockers, central nervous system depressants or stimulants, anti-inflammatories,
             anticoagulants, immunosuppressants, vitamins, antioxidants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Groups will be matched for gender, age and BMI</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naomi L Deacon, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>UCSD Pulmonary and Sleep Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naomi L Deacon, Ph.D.</last_name>
    <phone>619-471-9484</phone>
    <email>ndeacon@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Atul Malhotra, M.D.</last_name>
    <email>amalhotra@ucsd.edu</email>
  </overall_contact_backup>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Naomi Deacon</investigator_full_name>
    <investigator_title>Research Scholar</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

